Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : NV-5138
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Supernus Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Open-Label of SPN-820 in Adults With Major Depressive Disorder
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 01, 2024
Lead Product(s) : NV-5138
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Supernus Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : NV-5138
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Supernus Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase 2 Study of NV-5138 in Adults With Treatment Resistant Depression
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 04, 2021
Lead Product(s) : NV-5138
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Supernus Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : NV-5138
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Supernus Pharmaceuticals
Deal Size : $475.0 million
Deal Type : Collaboration
Details : Under the terms of the agreement, Supernus and Navitor will jointly conduct a Phase II clinical program for NV-5138 in treatment-resistant depression (TRD).
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : $25.0 million
April 21, 2020
Lead Product(s) : NV-5138
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Supernus Pharmaceuticals
Deal Size : $475.0 million
Deal Type : Collaboration
Lead Product(s) : NV-5138
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 30, 2018
Lead Product(s) : NV-5138
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable